Novoheart Holdings Inc (TSXV: NVH) is one of this year’s Venture 50 companies — the company is a global stem cell biotechnology company dedicated to engineering bioartificial human heart prototypes using state-of-the-art stem cell and bioengineering approaches.

The company’s mission and vision are to revolutionize drug discovery and development of heart therapeutics with our various proprietary bioengineered human heart constructs, and to further develop them into transplantable grafts for cell-based regenerative heart therapies with superior safety and efficacy.

The 2020 Venture 50 is a ranking of top performers on TSX Venture Exchange over the last year. The ranking comprises 10 companies from each of the five industry sectors, selected based on three equally weighted criteria: market capitalization growth, share price appreciation and trading volume.

For the full 2020 Venture 50 ranking, methodology and profile videos of companies included in the ranking, visit: www.tsx.com/venture50